Seer (SEER)
(Delayed Data from NSDQ)
$1.78 USD
+0.01 (0.56%)
Updated Aug 6, 2024 03:59 PM ET
After-Market: $1.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SEER 1.78 +0.01(0.56%)
Will SEER be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SEER based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SEER
Seer, Inc. (SEER) Reports Q1 Loss, Misses Revenue Estimates
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
SEER: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Other News for SEER
Seer to Report Second Quarter 2024 Financial Results on August 8, 2024
Seer Proteograph? Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
Seer announces publications highlighting studies on Proteograph Product Suite
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ?s Early Cancer Detection Study
Lab Instrument Industry Update - New Commercial Entrants